| Catalog No. | HV612016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q5ZPR3 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | MG-A271, 1353485-38-7 |
|---|
| Background | Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
